Beneficial Effects of Polysaccharides on the Epithelial Barrier Function in Intestinal Mucositis

Overview

Journal Front Physiol

Date 2021 Aug 9

PMID 34366901

Citations 11

Authors

Karien Sauruk da Silva

Bruna Carla da Silveira

Laryssa Regis Bueno

Liziane Cristine Malaquias da Silva

Lauany da Silva Fonseca

Elizabeth Soares Fernandes

Daniele Maria-Ferreira

Affiliations

Soon will be listed here.

Abstract

Intestinal mucositis is a clinically relevant side effect of anticancer therapies. It is experienced by 60-100% of patients undergoing treatment with high doses of chemotherapy, radiation therapy, and bone marrow transplantation. Intestinal mucositis can manifest as pain, weight loss, inflammation, diarrhea, rectal bleeding, and infection; affecting normal nutritional intake and intestinal function. It often impacts adherence to anticancer therapy as it frequently limits patient's ability to tolerate treatment, causing schedule delays, interruptions, or premature discontinuation. In some cases, local and systemic secondary infections are observed, increasing the costs toward medical care and hospitalization. Several strategies for managing mucositis are available which do not always halt this condition. In this context, new therapeutic strategies are under investigation to prevent or treat intestinal mucositis. Polysaccharides from natural resources have recently become promising molecules against intestinal damage due to their ability to promote mucosal healing and their anti-inflammatory actions. These effects are associated with the protection of intestinal mucosa and regulation of microbiota and immune system. This review aims to discuss the recent advances of polysaccharides from natural resources as potential therapies for intestinal mucositis. The source, species, doses, treatment schedules, and mechanisms of action of polysaccharides will be discussed in detail.

Citing Articles

Alginate's ability to prevent metabolic illnesses, the degradation of the gut's protective layer, and alginate-based encapsulation methods.

Ahmad A, Riaz S, Desta D Food Sci Nutr. 2024; 12(11):8692-8714.

PMID: 39619999 PMC: 11606899. DOI: 10.1002/fsn3.4455.

Structure-Function Relationships and Health-Promoting Properties of the Main Nutraceuticals of the Cactus Pear ( spp.) Cladodes: A Review.

Koufan M, Choukrane B, Mazri M Molecules. 2024; 29(19).

PMID: 39407660 PMC: 11477999. DOI: 10.3390/molecules29194732.

Benzimidazole Derivative (N-{4-[2-(4-Methoxyphenyl)-1H-Benzimidazole-1-Sulfonyl] Phenyl} Acetamide) Ameliorates Methotrexate-Induced Intestinal Mucositis by Suppressing Oxidative Stress and Inflammatory Markers in Mice.

Awais M, Zubair H, Nadeem H, Hill J, Ali J, Saleem A Inflammation. 2024; 47(4):1185-1203.

PMID: 38289578 DOI: 10.1007/s10753-024-01969-9.

Polysaccharides from Passion Fruit Peels: From an Agroindustrial By-Product to a Viable Option for 5-FU-Induced Intestinal Damage.

Sauruk da Silva K, Abboud K, Schiebel C, de Oliveira N, Bueno L, de Mello Braga L Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513823 PMC: 10383750. DOI: 10.3390/ph16070912.

Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.

Li Y, Zhang C, Feng L, Shen Q, Liu F, Jiang X Front Pharmacol. 2023; 14:1195104.

PMID: 37383719 PMC: 10293794. DOI: 10.3389/fphar.2023.1195104.

References

Maria-Ferreira D, Nascimento A, Cipriani T, Santana-Filho A, Watanabe P, Sant Ana D . Rhamnogalacturonan, a chemically-defined polysaccharide, improves intestinal barrier function in DSS-induced colitis in mice and human Caco-2 cells. Sci Rep. 2018; 8(1):12261. PMC: 6095889. DOI: 10.1038/s41598-018-30526-2. View

Zhang L, Zhang W, Wang Q, Wang D, Dong D, Mu H . Purification, antioxidant and immunological activities of polysaccharides from Actinidia Chinensis roots. Int J Biol Macromol. 2014; 72:975-83. DOI: 10.1016/j.ijbiomac.2014.09.056. View

Bowen J, Gibson R, Keefe D . Animal models of mucositis: implications for therapy. J Support Oncol. 2011; 9(5):161-8. DOI: 10.1016/j.suponc.2011.04.009. View

Kwon Y . Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. Onco Targets Ther. 2016; 9:2007-16. PMC: 4827894. DOI: 10.2147/OTT.S96899. View

Rubenstein E, Peterson D, Schubert M, Keefe D, McGuire D, Epstein J . Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004; 100(9 Suppl):2026-46. DOI: 10.1002/cncr.20163. View

Naidu M, Ramana G, Rani P, Krishna Mohan I, Suman A, Roy P . Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer. Neoplasia. 2004; 6(5):423-31. PMC: 1531648. DOI: 10.1593/neo.04169. View

Xiang D, Guo Y, Zhang J, Gao J, Lu H, Zhu S . Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model. Cancer Chemother Pharmacol. 2010; 67(6):1445-53. DOI: 10.1007/s00280-010-1439-1. View

Zhao Y, Zheng Y, Wang J, Ma S, Yu Y, White W . Fucoidan Extracted from : Source for Nutraceuticals/Functional Foods. Mar Drugs. 2018; 16(9). PMC: 6164441. DOI: 10.3390/md16090321. View

Blijlevens N, Sonis S . Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol. 2006; 18(5):817-26. DOI: 10.1093/annonc/mdl332. View

10.

Steimbach L, Borgmann A, Gomar G, Hoffmann L, Rutckeviski R, de Andrade D . Fungal beta-glucans as adjuvants for treating cancer patients - A systematic review of clinical trials. Clin Nutr. 2020; 40(5):3104-3113. DOI: 10.1016/j.clnu.2020.11.029. View

11.

Logan R, Stringer A, Bowen J, Gibson R, Sonis S, Keefe D . Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. Cancer Chemother Pharmacol. 2008; 63(2):239-51. DOI: 10.1007/s00280-008-0732-8. View

12.

Gibson R, Bowen J, Alvarez E, Finnie J, Keefe D . Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy. 2007; 53(5):360-9. DOI: 10.1159/000107458. View

13.

Cai B, Wan P, Sun H, Chen D, Chen H, Chen X . Protective Effects of Enteral Nutrition Supplemented with Crassostrea hongkongensis Polysaccharides Against 5-Fluorouracil-Induced Intestinal Mucosal Damage in Rats. J Med Food. 2018; 21(4):348-355. DOI: 10.1089/jmf.2017.4025. View

14.

Al-Dasooqi N, Sonis S, Bowen J, Bateman E, Blijlevens N, Gibson R . Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013; 21(11):3233-41. DOI: 10.1007/s00520-013-1900-x. View

15.

Li F, Luo P, Liu H . A Potential Adjuvant Agent of Chemotherapy: Sepia Ink Polysaccharides. Mar Drugs. 2018; 16(4). PMC: 5923393. DOI: 10.3390/md16040106. View

16.

Zhang Q, Wang F, Jia K, Kong L . Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects. Front Pharmacol. 2018; 9:1253. PMC: 6232953. DOI: 10.3389/fphar.2018.01253. View

17.

Ribeiro R, Wanderley C, V T Wong D, Mota J, Leite C, Souza M . Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemother Pharmacol. 2016; 78(5):881-893. DOI: 10.1007/s00280-016-3139-y. View

18.

Zhang L, Koyyalamudi S, Jeong S, Reddy N, Bailey T, Longvah T . Immunomodulatory activities of polysaccharides isolated from Taxillus chinensis and Uncaria rhyncophylla. Carbohydr Polym. 2013; 98(2):1458-65. DOI: 10.1016/j.carbpol.2013.07.060. View

19.

Friedman M . Mushroom Polysaccharides: Chemistry and Antiobesity, Antidiabetes, Anticancer, and Antibiotic Properties in Cells, Rodents, and Humans. Foods. 2017; 5(4). PMC: 5302426. DOI: 10.3390/foods5040080. View

20.

Sonis S . The pathobiology of mucositis. Nat Rev Cancer. 2004; 4(4):277-84. DOI: 10.1038/nrc1318. View